Neurophysiology of hearing in patients with mucopolysaccharidosis type IV

TitleNeurophysiology of hearing in patients with mucopolysaccharidosis type IV
Publication TypeJournal Article
Year of Publication2018
AuthorsNagao, K., Morlet T., Haley E., Padilla J., Nemith J., Mason R. W., & Tomatsu S.
JournalMolecular genetics and metabolism
Volume123
Issue4
Pagination472-478
Date Published2018 04
ISSN1096-7206
KeywordsActivities of Daily Living; Adolescent; Adult; Audiological testing; Audiometry, Pure-Tone; Auditory system; Auditory Threshold; Body Height; Child; Electrophysiology; Female; Follow-Up Studies; Hearing impairment/loss; Hearing Loss; Humans; Male; Mucopolysaccharidosis IV; Neurophysiology; Prevalence; Prognosis; United States; Young Adult
Abstract

BACKGROUND: Hearing impairment is a common problem in patients with mucopolysaccharidosis IV (MPS IV) throughout their life. Many of the adult patients with MPS IV exhibit permanent or severe hearing loss. However, there has been no systematic review of detailed audiological test results in MPS IV.
MATERIALS AND METHODS: Fourteen individuals with MPS IV (13 MPS IVA and 1 MPS IVB; aged between 12 and 38 years old) participated in the current study. We obtained auditory neurophysiological responses (auditory brainstem responses and otoacoustic emissions test) in addition to pure-tone audiometry and middle ear function tests (tympanometry and acoustic reflexes).
RESULTS: The results indicated various levels and types of hearing loss with abnormal neurophysiological responses even in those patients with MPS IVA with normal pure tone thresholds. We also found a strong relationship between height (short stature is an indicator of skeletal severity) and hearing sensitivity as well as a strong relationship between height and outer hair cell function in the inner ear (measured by otoacoustic emissions) among MPS IVA patients.
CONCLUSION: The strong correlation between reduced height and hearing loss indicates that patients with severe skeletal dysplasia may be at higher risk of developing more severe hearing loss. More importantly, the spectrum of hearing disorders indicates that MPS IV patients should have annual neurophysiological hearing tests in addition to audiometric testing from an early age regardless of their skeletal severity to more carefully monitor disease progression.

DOI10.1016/j.ymgme.2018.02.002
Alternate JournalMol. Genet. Metab
Refereed DesignationRefereed